Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (5982)	3/20/2002 8:30:35 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

george, PDLI news is old as it was made available at the AAD meeting. I thought they only recently broke the blinding on this study? Recall about a month ago a Cowen report, based on discussions they had had with investigators, claimed that the trial would be unfavorable, and the stock tanked then. Here's a quote from that report: ``Our consultants have indicated that, while the Zenapax psoriasis clinical trial is still blinded and the data have yet to be analyzed, the drug has not shown results to suggest the drug is apt to be efficacious,'' he said. Peter